U.S. OKs Novartis Gleevec to reduce recurring cancer
WASHINGTON (Reuters) - U.S. health regulators have approved Novartis' drug Gleevec to reduce the risk of cancer recurring in patients with a rare type of stomach cancer, Novartis said on Friday.<div class="feedflare">
<img src="http://feedproxy.google.com/~f/Reuters/domesticNews?d=41" border="0"></img> (http://feeds.reuters.com/~f/Reuters/domesticNews?a=LOxkx18K) <img src="http://feedproxy.google.com/~f/Reuters/domesticNews?i=cAXQIOFI" border="0"></img> (http://feeds.reuters.com/~f/Reuters/domesticNews?a=cAXQIOFI) <img src="http://feedproxy.google.com/~f/Reuters/domesticNews?i=KgwXHR5q" border="0"></img> (http://feeds.reuters.com/~f/Reuters/domesticNews?a=KgwXHR5q)
</div><img src="http://feedproxy.google.com/~r/Reuters/domesticNews/~4/FYRcqH1XP9o" height="1" width="1"/>
http://feeds.reuters.com/~r/Reuters/domesticNews/~3/FYRcqH1XP9o/idUSTRE4BJ08T20081220